

CYTOPOINT® is not a registered chemical product and contains lokivetmab which is not an approved active constituent. An application for registration of the product and approval of the active constituent has been submitted to the Australian Pesticides and Veterinary Medicines Authority (APVMA).

CYTOPOINT®

The first monoclonal antibody therapy for canine atopic dermatitis¹

CYTOPOINT is a new injectable that puts long-lasting control of canine atopic dermatitis in your hands¹



MANAGING ATOPIC DERMATITIS CAN BE A NIGHTMARE



REST EASY WITH CYTOPOINT®

1
MONTH
OF RELIEF*

CYTOPOINT®: the first monoclonal antibody to provide lasting relief from atopic itch, without steroid side-effects.



**RAPID,
SUSTAINED RELIEF**

Starts relieving itch within 8 hours and delivers a month of relief from the clinical signs of atopic dermatitis; in-clinic administration ensures compliance



**INNOVATIVE,
TARGETED THERAPY**

The first and only monoclonal antibody to target and neutralise interleukin (IL)-31, the key itch-inducing cytokine in atopic dermatitis



**UNPARALLELED
SAFETY PROFILE**

Can be used in dogs of all ages, even those with concomitant diseases or on other medications. No steroid side-effects

*Repeat administration monthly as needed in the individual patient.

Innovating for you. Introducing CYTOPOINT®, the breakthrough therapy for canine atopic dermatitis. A monthly injection that provides rapid and sustained relief from atopic itch.

Harnessing the power of the immune system

Monoclonal antibodies (mAbs) are produced in a laboratory from a single cell line. Like naturally produced antibodies, they **target and neutralise specific antigens**, without provoking an immune response from the host.

Stopping the itch cycle before it starts

Effective mAb therapy requires identification of a specific target(s) of most relevance to the disease process in question. Research over the past decade has shown that cytokines — intercellular protein messengers — play an important role in the cycle of itch and inflammation in canine atopic dermatitis.

A key cytokine in the cycle of itch and inflammation in canine atopic dermatitis is **interleukin (IL)-31**. IL-31 activates peripheral sensory nerves, which send an itch signal to the dog's brain.

CYTOPOINT is an anti-IL-31 monoclonal antibody that specifically targets and neutralises IL-31 to rapidly and effectively reduce clinical signs of canine atopic dermatitis. Because of the **exquisite specificity** in the targeting of IL-31, other cellular functions and immune responses are not adversely affected.

Rapid and sustained relief for canine patients, without steroid side-effects

CYTOPOINT **begins to reduce** clinical signs of atopic dermatitis **within 8 hours** and delivers a month of relief. In-clinic administration each month gives veterinarians more opportunities to monitor patients and deliver optimal care.

Along with itch relief, CYTOPOINT also leads to **improvement in skin condition**, giving the skin a chance to heal.

CYTOPOINT is indicated for **dogs of all ages**. Since the mAb mimics the dog's own antibodies, it is eliminated via normal protein degradation pathways that do not involve the kidneys or liver, thus avoiding potential side effects associated with traditional pharmacotherapy.

No drug interactions were observed in field studies where CYTOPOINT was administered concomitantly with other common medications including parasiticides, antibiotics, vaccines, anti-inflammatories and other antipruritics, such as Apoquel® (oclacitinib).

When will CYTOPOINT be available in Australia?

Zoetis has made a submission to the APVMA to gain registration of CYTOPOINT. Following registration we will confirm when Australian veterinarians will be able to offer this life-changing treatment option to their clients.

In the meantime, Apoquel is an excellent choice for relieving the itch associated with both allergic and atopic dermatitis.



Reference: 1. Data on file, Press Release, August 2015, Zoetis LLC.

Zoetis Australia Pty Ltd. ABN 94 156 476 425. Level 6, 5 Rider Boulevard, Rhodes NSW 2138.

zoetis © 2018 Zoetis Inc. All rights reserved. April 2018. MM-03297.

CYTOPOINT